ScholarLens Back to search
2008•Zhongguo yiyuan yongyao pingjia yu fenxiRequires access

Clinical Evaluation on Endothelin Receptor Antagonist for Hypertensive Pulmonary Vascular Disease

Zhang Shige

Open publisher page 0 citations

Abstract

OBJECTIVE:With the clarifying of the pathogenic mechanism of pulmonary arterial hypertension,a new endothelin receptor antagonist has become available in the market recently.The advances and clinical evaluation of endothelin receptor antagonist were discussed in this paper.METHODS:The pertinent literatures in recent years at home and abroad were reviewed.RESULTS CONCLUSION:Advance in endothelin receptor antagonist was rapid in recent years,and its inhibition on vasoconstriction of endothelin-1 and promotion on cell proliferation make it possible for treatment of arterial hypertension and cardiac insufficiency,which has become a golden drug key toward treatment for hypertensive pulmonary vascular disease.

About this research paper

What this paper is about

OBJECTIVE:With the clarifying of the pathogenic mechanism of pulmonary arterial hypertension,a new endothelin receptor antagonist has become available in the market recently.The advances and clinical evaluation of endothelin receptor antagonist were discussed in this paper.METHODS:The pertinent literatures in recent years at home and abroad were reviewed.RESULTS CONCLUSION:Advance in endothelin receptor antagonist was rapid in recent years,and its inhibition on vasoconstriction of endothelin-1 and promotion on cell proliferation make it possible for treatment of arterial hypertension and cardiac insufficiency,which has become a golden drug key toward treatment for hypertensive pulmonary vascular disease.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE:With the clarifying of the pathogenic mechanism of pulmonary arterial hypertension,a new endothelin receptor antagonist has become available in the market recently.The advances and clinical evaluation of endothelin receptor antagonist were discussed in this paper.METHODS:The pertinent literatures in recent years at home and abroad were reviewed.RESULTS CONCLUSION:Advance in endothelin receptor antagonist was rapid in recent years,and its inhibition on vasoconstriction of endothelin-1 and promotion on cell proliferation make it possible for treatment of arterial hypertension and cardiac insufficiency,which has become a golden drug key toward treatment for hypertensive pulmonary vascular disease.

Key concepts: Endothelin receptor, Endothelin receptor antagonist, Vasoconstriction, Antagonist, Medicine, Pulmonary hypertension, Receptor antagonist, Endothelin 1

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Evaluation on Endothelin Receptor Antagonist for Hypertensive Pulmonary Vascular Disease — Research Paper | ScholarLens